Sickness fund rejects unfair DMP (disease management programme) competition
This article was originally published in Clinica
Executive Summary
German sickness funds must standardise their disease management programmes in order to avoid potentially damaging competition, says the guilds' sickness fund (IKK). "If the DMPs are to conform to a unified scientific standard, then there can only be one level of care," said the joint chairman of the IKK's advisory board, Uwe Konrad. Mr Konrad also stressed that standardisation of the programmes must be accompanied by a unified reimbursement system. He added that, although a certain level of competition was essential, in terms of the DMPs, this should only apply to supplementary, rather than standard procedures.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.